Comparison 1. Comparison 1: HALOPERIDOL versus LOW‐POTENCY ANTIPSYCHOTIC DRUGS.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Response to treatment	14	574	Risk Ratio (M‐H, Random, 95% CI)	1.11 [0.86, 1.44]
2 Mental state: 1a. General ‐ overall symptoms ‐ average endpoint score/change (BPRS, high = poor)	4	133	Mean Difference (IV, Random, 95% CI)	‐0.09 [‐2.15, 1.96]
3 Mental state: 1b. General ‐ overall symptoms ‐ average endpoint score/change (PANSS, high = poor)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1 total	1	41	Mean Difference (IV, Random, 95% CI)	‐4.0 [‐20.69, 12.69]
3.2 positive	1	41	Mean Difference (IV, Random, 95% CI)	‐1.0 [‐6.77, 4.77]
3.3 negative	1	41	Mean Difference (IV, Random, 95% CI)	‐0.10 [‐5.20, 5.00]
4 Global state: Average endpoint score/change (CGI, high = poor)	3	117	Mean Difference (IV, Random, 95% CI)	0.09 [‐0.31, 0.50]
5 Relapse	5	141	Risk Ratio (M‐H, Random, 95% CI)	0.64 [0.26, 1.57]
6 Leaving the study early	11		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.1 due to any reason	11	408	Risk Ratio (M‐H, Random, 95% CI)	0.82 [0.38, 1.77]
6.2 due to adverse effects	11	408	Risk Ratio (M‐H, Random, 95% CI)	0.44 [0.16, 1.20]
6.3 due to inefficacy	10	378	Risk Ratio (M‐H, Random, 95% CI)	0.63 [0.31, 1.29]
7 Adverse effects: 1. General ‐ at least one adverse effect	5	158	Risk Ratio (M‐H, Random, 95% CI)	1.97 [0.69, 5.66]
8 Adverse effects: 2a. Specific ‐ movement disorders	12		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
8.1 at least one movement disorder	5	170	Risk Ratio (M‐H, Random, 95% CI)	1.64 [1.22, 2.21]
8.2 akathisia	4	160	Risk Ratio (M‐H, Random, 95% CI)	1.27 [0.56, 2.90]
8.3 dyskinesia	1	38	Risk Ratio (M‐H, Random, 95% CI)	3.0 [0.34, 26.33]
8.4 dystonia	5	193	Risk Ratio (M‐H, Random, 95% CI)	4.71 [1.95, 11.36]
8.5 loss of associated movement	1	86	Risk Ratio (M‐H, Random, 95% CI)	7.33 [0.39, 137.68]
8.6 oculogyric crisis	1	86	Risk Ratio (M‐H, Random, 95% CI)	3.14 [0.13, 74.98]
8.7 rigor	1	16	Risk Ratio (M‐H, Random, 95% CI)	5.0 [0.28, 90.18]
8.8 tremor	2	127	Risk Ratio (M‐H, Random, 95% CI)	2.17 [0.16, 29.13]
8.9 use of antiparkinson medication	6	165	Risk Ratio (M‐H, Random, 95% CI)	2.88 [1.19, 7.00]
9 Adverse effects: 2b. Specific ‐ movement disorders ‐ average endpoint score/change (ESRS, high = poor)	2	78	Mean Difference (IV, Random, 95% CI)	2.01 [1.35, 2.68]
10 Adverse effects: 3. Others	9		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
10.1 allergy ‐ allergic reactions	1	86	Risk Ratio (M‐H, Random, 95% CI)	3.14 [0.13, 74.98]
10.2 allergy ‐ rash	1	38	Risk Ratio (M‐H, Random, 95% CI)	3.0 [0.13, 69.31]
10.3 allergy ‐ tongue alterations	1	86	Risk Ratio (M‐H, Random, 95% CI)	0.50 [0.28, 0.90]
10.4 anticholinergic ‐ blurring of vision	2	124	Risk Ratio (M‐H, Random, 95% CI)	0.78 [0.35, 1.70]
10.5 anticholinergic ‐ constipation	3	155	Risk Ratio (M‐H, Random, 95% CI)	1.53 [0.21, 11.20]
10.6 anticholinergic ‐ drooling	1	86	Risk Ratio (M‐H, Random, 95% CI)	2.10 [0.20, 22.26]
10.7 anticholinergic ‐ dry mouth	4	195	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.63, 1.15]
10.8 anticholinergic ‐ micturition disturbances	1	41	Risk Ratio (M‐H, Random, 95% CI)	0.21 [0.01, 4.11]
10.9 anticholinergic ‐ repercussions on sexual life	1	41	Risk Ratio (M‐H, Random, 95% CI)	0.21 [0.01, 4.11]
10.10 anticholinergic ‐ sweating	1	41	Risk Ratio (M‐H, Random, 95% CI)	3.15 [0.36, 27.83]
10.11 anticholinergic ‐ urinary retention	1	86	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
10.12 cardiovascular ‐ ankle edema	1	28	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
10.13 cardiovascular ‐ dizziness	2	127	Risk Ratio (M‐H, Random, 95% CI)	0.36 [0.21, 0.62]
10.14 cardiovascular ‐ hypotension	6	251	Risk Ratio (M‐H, Random, 95% CI)	0.32 [0.10, 1.07]
10.15 cardiovascular ‐ orthostatic symptoms	1	41	Risk Ratio (M‐H, Random, 95% CI)	0.35 [0.16, 0.78]
10.16 cardiovascular ‐ palpitations	1	41	Risk Ratio (M‐H, Random, 95% CI)	0.30 [0.07, 1.28]
10.17 cardiovascular ‐ syncope	1	86	Risk Ratio (M‐H, Random, 95% CI)	0.15 [0.01, 2.81]
10.18 central nervous system ‐ asthenia	1	41	Risk Ratio (M‐H, Random, 95% CI)	2.10 [0.98, 4.51]
10.19 central nervous system ‐ confusion	1	30	Risk Ratio (M‐H, Random, 95% CI)	2.65 [0.12, 60.21]
10.20 central nervous system ‐ excitement	1	28	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
10.21 central nervous system ‐ headache	2	127	Risk Ratio (M‐H, Random, 95% CI)	2.67 [0.50, 14.19]
10.22 central nervous system ‐ nausea	1	86	Risk Ratio (M‐H, Random, 95% CI)	1.57 [0.28, 8.94]
10.23 central nervous system ‐ photosensitivity	3	134	Risk Ratio (M‐H, Random, 95% CI)	0.41 [0.05, 3.39]
10.24 central nervous system ‐ sedation	2	44	Risk Ratio (M‐H, Random, 95% CI)	0.30 [0.11, 0.82]
10.25 central nervous system ‐ sleep disturbances	1	41	Risk Ratio (M‐H, Random, 95% CI)	6.30 [0.83, 47.80]
10.26 central nervous system ‐ somnolence	5	224	Risk Ratio (M‐H, Random, 95% CI)	0.91 [0.49, 1.72]
10.27 hormonal ‐ amenorrhoea	1	86	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
10.28 metabolic ‐ weight gain	3	88	Risk Ratio (M‐H, Random, 95% CI)	0.22 [0.06, 0.81]
10.29 metabolic ‐ weight loss	2	68	Risk Ratio (M‐H, Random, 95% CI)	0.60 [0.06, 6.06]